Combination drug therapy for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new combination of two targeted drugs for advanced triple-negative breast cancer. It aims to see if the combination can help stop the cancer from growing, and it may be an option if you've already tried standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of triple-negative breast cancer (your doctor will confirm if your cancer is 'triple-negative').
- Your cancer must have spread or be unable to be removed with surgery, and you must have already tried at least one standard treatment (like chemotherapy) that did not work or caused side effects.
- You should be generally active and able to care for yourself (your doctor will check this).
- You must have measurable tumors (seen on scans like CT or MRI) — not just in skin or bone.
- If you had brain metastases, they must be stable for at least 4 weeks after treatment, and you must not be on steroids for them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
This study compares a new combination of drugs (sacituzumab govitecan and pembrolizumab) against standard chemotherapy after you have already had initial chemotherapy. The aim is to see if the new combination shrink more breast cancers before surgery in people with triple-negative breast cancer.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.